Providing actionable clinical insights with
our epigenomics based workflows and know-how
Reporting actionable epigenomic information and analyses from proprietary pipelines and predictive models
Targeting cancers with higher Asian prevalence
Leveraging Asian epigenomics data for novel drug and biomarker discovery
Auristone was proud to present a poster titled “Transcriptomic analysis of HER2 expression in metastatic breast cancer: Insights from a UAE patient cohort” at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025.
At the 2025 ASCO Gastrointestinal Cancers Symposium, Auristone presented its first poster at the GI-focused meeting, titled “Transcriptomic features of Epstein-Barr virus-associated gastric cancer based on PD-L1 status.”
Auristone is pleased to announce a strategic partnership with South Korea’s leading genomic company, IMBdx, to offer a bundled solution combining genomic and epigenomic profiling for enhanced clinical insights.
Auristone is proud to receive the annual T-Up Emerging Awards together with Mr Goh Weixun. This recognizes the exceptional contributions of A*STAR Research Scientists and Engineers (RSEs) to local enterprises such as Auristone, in helping companies achieve significant milestones in their businesses.
Join Auristone and MiRXES for the Memorandum of Understanding (MOU) signing ceremony at the 33rd Annual Scientific Congress of Malaysian Oncological Society (ASCOMOS) at Kuala Lumpur (KL), Malaysia on November 4, 2022 at 5.30 PM.
This webinar discusses the current challenges and advances of immunotherapy using Immune Checkpoint Inhibitors (ICIs) combinations in MSS CRC.
Interested in working with us? Drop us a note below and we’ll get back to you as soon as we can.
enquiry@auristone.com
LaunchPad @ one-north
77 Ayer Rajah Crescent #01-27 Singapore 139954
